Harmony Biosciences Holdings logo

Harmony Biosciences Holdings(HRMY)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$33.76
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for HRMY

11/13/2026: HRMY (1-star) is currently NOT-A-BUY. Pass it for now.

Harmony Biosciences Holdings is a commercial-stage biopharmaceutical stock known for solid profitability and strong operating margins driven by its flagship narcolepsy therapy, WAKIX. The company's primary investment appeal lies in its reliable cash generation, low valuation multiple, and ongoing pipeline expansion into rare neurological conditions. However, investors face single-product revenue concentration and clinical execution risks as it attempts to diversify beyond WAKIX. The stock suits value and growth investors seeking profitable healthcare exposure, provided they monitor ongoing patent defenses and clinical trial readouts.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitHarmony delivers attractive organic revenue growth and expanding earnings through its core commercial portfolio.
Momentum investorStrong fit while signal remains positiveThe stock attracts technical interest during positive clinical readouts and regulatory approval catalysts.
Value investorStrong fitThe company trades at a notably low trailing P/E multiple relative to its profitability and growth rate.
Dividend investorWeak fitHarmony does not pay a dividend, focusing capital instead on reinvestment and pipeline expansion.
Low-risk investorMixed fitWhile profitable and financially sound, single-product concentration and biotech clinical risks introduce volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highBiotechnology equities often experience sharp price movements surrounding clinical trial data readouts and regulatory decisions.
Valuation riskLowThe stock trades at a conservative earnings multiple, mitigating severe downside valuation compression.
Competition risk (CNS and narcolepsy therapeutics)MediumIntense market rivalry from established players like Jazz Pharmaceuticals requires ongoing commercial execution.
Business qualityStrongThe company boasts high operating margins, strong cash flows, and proven commercial capabilities.
Dividend incomeLow / noneIncome-focused investors will find no dividend support as earnings are reinvested.
Execution riskMediumSuccess relies heavily on clinical trial delivery for pipeline assets and defending market share for WAKIX.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.98B USD
Price to earnings Ratio 11.18
1Y Target Price 48.08
Price to earnings Ratio 11.18
1Y Target Price 48.08
Volume (30-day avg) 1.1M shares
Beta 0.98
52 Weeks Range 25.90 - 43.49
Updated Date 11/15/2026
52 Weeks Range 25.90 - 43.49
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 3.02

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -10.82%
Avg. Invested days 38
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
HRMY receives a 4-star rating, supported by strong unit economics, solid company fundamentals, and solid analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
HRMY has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, moderate earnings growth (+9.1%) and strong cash generation (FCF margin 40.1%) are partially offset by modest insider ownership of 2.11%.

Financial Health Rating

★★★★★
HRMY's financial health is supported by strong liquidity, including working-capital and asset support (WC/assets 51.5%). Operating efficiency is solid (4 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is HRMY's strongest growth driver at +59.1% FY2025 versus FY2024 (strong, 5 stars). By comparison, revenue growth (+21.5%, solid) is also solid, while earnings growth (+9.1%, moderate) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 104.1% and approximately 89.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 2.11% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 12.09%
FMR Inc 6.09%
American Century Companies Inc 5.30%
Vanguard Portfolio Management, LLC 4.91%
Dimensional Fund Advisors, Inc. 4.51%

Unit Economics (Per $1K Revenue)

★★★★★
HRMY generates approximately $772 of gross profit, $240 of operating income, and $401 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

★★★★★
Effective Tax Rate: 26.21%

Quantitative Style Profile

★★★★★
HRMY has a high-quality, liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedQuality TiltSmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
U.S. Commercial PharmaceuticalsNet product sales generated primarily from the commercialization of WAKIX (pitolisant) in the United States market.Virtually all of Harmony's revenue comes from selling its flagship narcolepsy drug to patients in the U.S.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-04
When Before Market
Estimate 1
Actual 0.81

Profitability

Profit Margin 18.05%
Operating Margin (TTM) 22.17%

Management Effectiveness

Return on Assets (TTM) 10.21%
Return on Equity (TTM) 18.73%

Valuation

Trailing PE 11.18
Forward PE 8.38
Enterprise Value 1.36B
Price to Sales(TTM) 2
Enterprise Value 1.36B
Price to Sales(TTM) 2
Enterprise Value to Revenue 1.37
Enterprise Value to EBITDA 5.01
Shares Outstanding 58.72M
Shares Floating 52.58M
Shares Outstanding 58.72M
Shares Floating 52.58M
Percent Insiders 2.11
Percent Institutions 104.14

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.